Market Exclusive

Amedisys Inc (NASDAQ:AMED) price target raised to $115.00 by Royal Bank of Canada

Analyst Ratings For Amedisys Inc (NASDAQ:AMED)

Today, Royal Bank of Canada raised its price target on Amedisys Inc (NASDAQ:AMED) to $115.00 per share.

There are 8 Buy Ratings, 3 Hold Ratings, no Strong Buy Ratings, no Sell Ratings on the stock.

The current consensus rating on Amedisys Inc (NASDAQ:AMED) is Buy with a consensus target price of $76.80 per share, a potential 28.76% downside.

Some recent analyst ratings include

Recent Insider Trading Activity For Amedisys Inc (NASDAQ:AMED)
Amedisys Inc (NASDAQ:AMED) has insider ownership of 2.60% and institutional ownership of 93.70%.

About Amedisys Inc (NASDAQ:AMED)
Amedisys, Inc., together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and Personal Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses, physical and speech therapists, occupational therapists, and aides for its patients to complete their important personal tasks. The Hospice segment offers care that is designed to provide comfort and support for those who are dealing with a terminal illness, including heart disease, pulmonary disease, Alzheimer's, HIV/AIDS, and cancer. The Personal Care segment provides assistance for patients with the activities of daily living. As of February 27, 2018, the company owned and operated 421 care centers in 34 states. Amedisys, Inc. was founded in 1982 and is headquartered in Baton Rouge, Louisiana.

Recent Trading Activity for Amedisys Inc (NASDAQ:AMED)
Shares of Amedisys Inc closed the previous trading session at 108,08 up +2,07 1,95 % with 106.54 shares trading hands.

Exit mobile version